英文药名: Coly-Mycin M(Colistimethate Sodium Injection Vial)
中文药名: 多粘菌素E甲磺酸钠注射剂
药生产厂家: Erfa
药品名称
多粘菌素E甲磺酸钠 Colistimethate Sodium
中文别名：多粘菌素E甲磺酸钠、肠粘菌素甲磺酸钠、甲磺酸粘菌素、粘菌素甲磺酸钠、粘菌素甲烷磺酸钠
英文别名：Colimicina、Colimycine、Colistimethate、Colistimethatum Natricum、Colistin Sodium Methamesulfonate、Colistin Sulphomethate Sodium、Colistinm、Colistinmethane Sulfonate Sodium、Coly-Mycin、Coly-Mycin M、Methacolimycin、Pentasodium Colitinmethanesulfate
药品类别：其它抗生素类抗感染药
适应症
本品为绿脓杆菌感染的首选药物之一，可治绿脓杆菌性脑膜炎，也可用于败血症、泌尿系统、腹部及其它手术后感染。
用法用量
肌注或皮注：每次１００万单位，１日２～４次。或遵医嘱！
注意事项
主要为肾毒性及神经毒性，但比硫酸多粘菌素Ｅ小。有时会出现暂时性的感觉异常、皮肤瘙痒、视觉障碍、语言紊乱、药物热、胃肠道菌群失调等。肾功能不全者慎用。
规格
粉针剂：150mg。
COLY-MYCIN M - colistimethate sodium injection
JHP Pharmaceuticals LLC
Coly-Mycin® M Parenteral (Colistimethate for Injection, USP)
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Coly-Mycin M and other antibacterial drugs, Coly-Mycin M should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
FOR INTRAMUSCULAR AND INTRAVENOUS USE
DESCRIPTION
Coly-Mycin® M Parenteral (Colistimethate for Injection, USP) is a sterile parenteral antibiotic product which, when reconstituted (see Reconstitution), is suitable for intramuscular or intravenous administration.
Each vial contains colistimethate sodium or pentasodium colistinmethanesulfonate (150 mg colistin base activity).
Colistimethate sodium is a polypeptide antibiotic with an approximate molecular weight of 1750. The empirical formula is C58H105N16Na5O28S5 and the structural formula is represented below:
CLINICAL PHARMACOLOGY
Typical serum and urine levels following a single 150 mg dose of Coly-Mycin M Parenteral IM or IV in normal adult subjects are shown in Figure 1.
Higher serum levels were obtained at 10 minutes following IV administration. Serum concentration declined with a half-life of 2–3 hours following either intravenous or intramuscular administration in adults and in the pediatric population, including premature infants.
Average urine levels ranged from about 270 mcg/mL at 2 hours to about 15 mcg/mL at 8 hours after intravenous administration and from 200 to about 25 mcg/mL during a similar period following intramuscular administration.
Microbiology
Colistimethate sodium is a surface active agent which penetrates into and disrupts the bacterial cell membrane. It has been shown to have bactericidal activity against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section:
Aerobic gram-negative microorganisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii.
Susceptibility Tests
Colistin is classified under Group C for routine testing and reporting by clinical microbiology laboratories.1
Dilution techniques
Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). MIC is the lowest concentration of an antimicrobial agent that prevents visible growth of a microorganism in an agar or broth dilution susceptibility test. These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method 1,2 (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of colistin powder. Use only the dilution technique (MICs) for testing Acinetobacter spp. and other non-Enterobacteriaceae as no Disk diffusion (zone diameter) interpretive criteria have been established for their testing. The MIC values should be interpreted according to the following criteria:
| Pathogen | (MIC) Minimum Inhibitory Concentrations (µg/mL)1,* | ||
|---|---|---|---|
| S | I | R | |
| |||
| Pseudomonas aeruginosa | ≤ 2 | 4 | ≥ 8 |
| Acinetobacter spp. | ≤ 2 | - | ≥ 4 |
| Other non-Enterobacteriaceae† | ≤ 2 | 4 | ≥ 8 |
Standardized susceptibility test procedures require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. The acceptable limits for Quality Control strains for dilution technique are as follows:
| QC strain | (MIC) Minimum Inhibitory Concentrations (µg/mL)1,* |
|---|---|
| |
| Escherichia coli ATCC 25922 |
0.25-1 |
| Pseudomonas aeruginosa ATCC 27853 |
0.25-2 |
Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure1 requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 10-µg of colistin to test the susceptibility of microorganisms to colistin. Do not use diffusion technique for testing Acinetobacter spp. and other non-Enterobacteriaceae as no Disk diffusion (zone diameter) interpretive criteria have been established for their testing. The disk diffusion values should be interpreted according to the following criteria:
| Pathogen | Disk Diffusion (zone diameters in nearest whole mm)1,* | ||
|---|---|---|---|
| S | I | R | |
| |||
| Pseudomonas aeruginosa | ≥ 11 | - | ≤ 10 |
Standardized susceptibility test procedures require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. The acceptable limits for Quality Control strains for diffusion technique are as follows:
| QC strain | Disk Diffusion (zone diameters in nearest whole mm)1,* |
|---|---|
| |
| Escherichia coli ATCC 25922 |
11-17 |
| Pseudomonas aeruginosa ATCC 27853 |
11-17 |
A report of 'Susceptible' implies that isolates are inhibited by the usually achievable concentrations of antimicrobial agent when the recommended dosage is used for the site of infection.
A report of 'Intermediate' indicates that the results should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. It implies clinical efficacy in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation.
A report of 'Resistant' indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.
INDICATIONS AND USAGE
Coly-Mycin M Parenteral is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa. This antibiotic is not indicated for infections due to Proteus or Neisseria. Coly-Mycin M Parenteral has proven clinically effective in treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii.
Coly-Mycin M Parenteral may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Coly-Mycin M and other antibacterial drugs, Coly-Mycin M should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
CONTRAINDICATIONS
The use of Coly-Mycin M Parenteral is contraindicated for patients with a history of sensitivity to the drug or any of its components.
WARNINGS
Maximum daily dose should not exceed 5 mg/kg/day (2.3 mg/lb) with normal renal function.
Transient neurological disturbances may occur. These include circumoral paresthesia or numbness, tingling or formication of the extremities, generalized pruritus, vertigo, dizziness, and slurring of speech. For these reasons, patients should be warned not to drive vehicles or use hazardous machinery while on therapy. Reduction of dosage may alleviate symptoms. Therapy need not be discontinued, but such patients should be observed with particular care.
Nephrotoxicity can occur and is probably a dose-dependent effect of colistimethate sodium. These manifestations of nephrotoxicity are reversible following discontinuation of the antibiotic.
Overdosage can result in renal insufficiency, muscle weakness, and apnea (see OVERDOSAGE section). See PRECAUTIONS, Drug Interactions subsection for use concomitantly with other antibiotics and curariform drugs.
Respiratory arrest has been reported following intramuscular administration of colistimethate sodium. Impaired renal function increases the possibility of apnea and neuromuscular blockade following administration of colistimethate sodium. Therefore, it is important to follow recommended dosing guidelines. See DOSAGE AND ADMINISTRATION section for use in renal impairment.
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Coly-Mycin M Parenteral, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
PRECAUTIONS
General
Since Coly-Mycin M Parenteral is eliminated mainly by renal excretion, it should be used with caution when the possibility of impaired renal function exists. The decline in renal function with advanced age should be considered.
When actual renal impairment is present, Coly-Mycin M Parenteral may be used, but the greatest caution should be exercised and the dosage should be reduced in proportion to the extent of the impairment. Administration of amounts of Coly-Mycin M Parenteral in excess of renal excretory capacity will lead to high serum levels and can result in further impairment of renal function, initiating a cycle which, if not recognized, can lead to acute renal insufficiency, renal shutdown, and further concentration of the antibiotic to toxic levels in the body. At this point, interference of nerve transmission at neuromuscular junctions may occur and result in muscle weakness and apnea (see OVERDOSAGE section).
Signs indicating the development of impaired renal function include: diminishing urine output, rising BUN and serum creatinine and decreased creatinine clearance. Therapy with Coly-Mycin M Parenteral should be discontinued immediately if signs of impaired renal function occur. However, if it is necessary to reinstate the drug, dosing should be adjusted accordingly after drug plasma levels have fallen (see DOSAGE AND ADMINISTRATION section).
Prescribing Coly-Mycin M in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Drug Interactions
Certain other antibiotics (aminoglycosides and polymyxin) have also been reported to interfere with the nerve transmission at the neuromuscular junction. Based on this reported activity, they should not be given concomitantly with Coly-Mycin M Parenteral except with the greatest caution.
Curariform muscle relaxants (e.g., tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
Sodium cephalothin may enhance the nephrotoxicity of Coly-Mycin M Parenteral. The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term animal carcinogenicity studies and genetic toxicology studies have not been performed with colistimethate sodium. There were no adverse effects on fertility or reproduction in rats at doses of 9.3 mg/kg/day (0.30 times the maximum daily human dose when based on mg/m2).
Pregnancy
Teratogenic Effects
Pregnancy Category C
Colistimethate sodium given intramuscularly during organogenesis to rabbits at 4.15 and 9.3 mg/kg resulted in talipes varus in 2.6% and 2.9% of fetuses, respectively. These doses are 0.25 and 0.55 times the maximum daily human dose based on mg/m2. In addition, increased resorption occurred at 9.3 mg/kg. Colistimethate sodium was not teratogenic in rats at 4.15 or 9.3 mg/kg. These doses are 0.13 and 0.30 times the maximum daily human dose based on mg/m2. There are no adequate and well-controlled studies in pregnant women. Since colistimethate sodium is transferred across the placental barrier in humans, it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers
It is not known whether colistimethate sodium is excreted in human breast milk. However, colistin sulphate is excreted in human breast milk. Therefore, caution should be exercised when colistimethate sodium is administered to nursing women.
Geriatric Use
Clinical studies of colistemethate sodium did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Pediatric Use
In clinical studies, colistimethate sodium was administered to the pediatric population (neonates, infants, children and adolescents). Although adverse reactions appear to be similar in the adult and pediatric populations, subjective symptoms of toxicity may not be reported by pediatric patients. Close clinical monitoring of pediatric patients is recommended.
Information for Patients
Patients should be counseled that antibacterial drugs including Coly-Mycin M should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Coly-Mycin M is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectivenss of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Coly-Mycin M or other antibacterial drugs in the future.
Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
ADVERSE REACTIONS
The following adverse reactions have been reported:
Gastrointestinal: gastrointestinal upset
Nervous System: tingling of extremities and tongue, slurred speech, dizziness, vertigo and paresthesia
Integumentary: generalized itching, urticaria and rash
Body as a Whole: fever
Laboratory Deviations: increased blood urea nitrogen (BUN), elevated creatinine and decreased creatinine clearance
Respiratory System: respiratory distress and apnea
Renal System: nephrotoxicity and decreased urine output
OVERDOSAGE
Overdosage with colistimethate sodium can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death. Overdosage with the drug can also cause acute renal failure, manifested as decreased urine output and increases in serum concentrations of BUN and creatinine.
As in any case of overdose, colistimethate sodium therapy should be discontinued and general supportive measures should be utilized.
It is unknown whether colistimethate sodium can be removed by hemodialysis or peritoneal dialysis in overdose cases.
DOSAGE AND ADMINISTRATION
Important: Coly-Mycin M Parenteral is supplied in vials containing colistimethate sodium equivalent to 150 mg colistin base activity per vial.
Reconstitution
The 150 mg vial should be reconstituted with 2.0 mL Sterile Water for Injection, USP. The reconstituted solution provides colistimethate sodium at a concentration equivalent to 75 mg/mL colistin base activity.
During reconstitution swirl gently to avoid frothing.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If these conditions are observed, the product should not be used.
Dosage
Adults and pediatric patients—Intravenous or Intramuscular Administration
Coly-Mycin M Parenteral should be given in 2 to 4 divided doses at dose levels of 2.5 to 5 mg/kg per day for patients with normal renal function, depending on the severity of the infection.
In obese individuals, dosage should be based on ideal body weight.
The daily dose should be reduced in the presence of renal impairment. Modifications of dosage in the presence of renal impairment are presented in Table 1.
| Renal Function | Degree of Impairment | |||
|---|---|---|---|---|
| Normal | Mild | Moderate | Considerable | |
| Plasma creatinine, mg/100 mL | 0.7–1.2 | 1.3–1.5 | 1.6–2.5 | 2.6–4.0 |
| Urea clearance,% of normal | 80–100 | 40–70 | 25–40 | 10–25 |
| Dosage | ||||
| Unit dose of Coly-Mycin M, mg | 100–150 | 75–115 | 66–150 | 100–150 |
| Frequency, times/day | 4 to 2 | 2 | 2 or 1 | every 36 hr |
| Total daily dose, mg | 300 | 150–230 | 133–150 | 100 |
| Approximate daily dose, mg/kg/day | 5.0 | 2.5–3.8 | 2.5 | 1.5 |
Note: The suggested unit dose is 2.5–5 mg/kg; however, the time INTERVAL between injections should be increased in the presence of impaired renal function.
| INTRAVENOUS ADMINISTRATION |
|---|
There are not sufficient data to recommend usage of Coly-Mycin M Parenteral with other drugs or other than the above listed infusion solutions. Administer the second half of the total daily dose by slow intravenous infusion, starting 1 to 2 hours after the initial dose, over the next 22 to 23 hours. In the presence of impaired renal function, reduce the infusion rate depending on the degree of renal impairment. The choice of intravenous solution and the volume to be employed are dictated by the requirements of fluid and electrolyte management. Any infusion solution containing colistimethate sodium should be freshly prepared and used for no longer than 24 hours. |
Coly-Mycin M Parenteral is supplied in vials containing colistimethate sodium (equivalent to 150 mg colistin base activity per vial) as a white to slightly yellow Iyophilized cake and is available as one vial per carton (NDC 42023-107-01).
Store between 20°–25°C (68°–77°F). (See USP controlled room temperature.)
Store reconstituted solution in refrigerator 2°–8°C (36°–46°F) or between 20°–25°C (68°–77°F) and use within 7 days.
-----------------------------------------------------
产地国家: 加拿大
原产地英文商品名:
Colymycin M 150mg 1 unit
原产地英文药品名:
colistimethate sodium
中文参考商品译名:
肠杆菌素M 多胜菌素甲 150毫克
中文参考药品译名:
粘菌素甲磺酸五钠
生产厂家英文名:
Erfa
